Cosmos Health Inc. (COSM) is a small-capitalization, vertically integrated healthcare group that develops, manufactures, and distributes a broad range of pharmaceuticals, nutraceuticals, cosmetics, biocides, and medical devices. Incorporated in Nevada and headquartered in Greece, the company operates a global platform that has drawn investor attention for its international expansion, its portfolio of proprietary consumer-health brands, and its ambitions in telehealth and artificial-intelligence-driven drug discovery. From what I see, its combination of manufacturing control and distribution reach sets it apart in the micro-cap space.
Cosmos Health was incorporated in Nevada in 2009 and maintains its principal executive offices in Thessaloniki, Greece, with additional offices and distribution centers in Athens and in Harlow, United Kingdom. The company describes itself as a diversified, vertically integrated global healthcare group, meaning it seeks to control multiple stages of the value chain, from manufacturing through distribution.
The company owns a portfolio of proprietary brands. Sky Premium Life and Mediterranation are its nutraceutical and food-supplement lines, while bio-bebe covers baby foods. C-Sept and C-Scrub are branded biocides and antiseptic products. Through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), Cosmos Health manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union.
The company's financial profile is built on several complementary segments. Its wholesale distribution business supplies branded generics, over-the-counter (OTC) medications, and parapharmaceuticals to retail pharmacies and wholesale distributors, primarily in Greece and the United Kingdom. Its pharmaceutical manufacturing division provides contract manufacturing for third parties while also producing the company's own products. Finally, its branded nutraceuticals segment generates higher-margin revenue through proprietary products sold across more than 40 countries.
Cosmos Health has also entered the telehealth market through its acquisition of ZipDoctor, Inc., a Texas-based platform, and it conducts research and development targeting major health conditions such as obesity, diabetes, and cancer. Its R&D efforts include the Cloudscreen artificial-intelligence drug-repurposing platform and a focus on repurposing existing drug candidates. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Investors follow COSM primarily because of its positioning as a diversified healthcare platform with multiple growth levers. The company's vertical integration, combining European GMP-certified manufacturing with an established wholesale distribution network, gives it a degree of control over both supply and distribution that is relatively unusual for a company of its size.
Several long-term growth drivers attract attention. The company has been expanding its proprietary, higher-margin brands, most notably its Sky Premium Life nutraceutical line, into new international markets including the United Arab Emirates and other Gulf markets. It has also begun entering the United States through a direct-to-consumer product platform manufactured in GMP-certified, FDA-registered facilities. Management has publicly articulated an ambition to shift its revenue mix toward proprietary products and contract manufacturing, which generally carry higher gross margins than wholesale distribution.
The company's R&D initiatives in oncology drug repurposing and obesity treatments, supported by artificial intelligence, represent an additional, longer-horizon opportunity. Its entry into telehealth through ZipDoctor further extends the platform into digital healthcare services. For investors focused on healthcare, pharmaceuticals, and small-cap growth companies, Cosmos Health's combination of manufacturing, distribution, branded products, and R&D makes it a distinctive, if speculative, name in the sector.
Investing in Cosmos Health carries significant risks that investors should understand. Most importantly, the company has reported recurring net losses and negative operating cash flow, and in its regulatory filings it has disclosed substantial doubt about its ability to continue as a going concern. This means the company has relied on access to capital markets to sustain its operations.
The company also faces concentration and macroeconomic risks. The substantial majority of its revenue is generated outside the United States and is denominated in foreign currencies, exposing results to currency-exchange fluctuations. Its wholesale distribution business depends on a relatively small number of large pharmaceutical wholesalers, a customer base that has undergone significant consolidation and gained purchasing leverage, which can pressure pricing. Pharmaceutical and nutraceutical markets are also highly regulated, and changes in European Union or U.S. regulation could affect the company's operations.
As a micro-capitalization company, Cosmos Health has a limited operating history at its current scale, a small market capitalization, and shares that can experience considerable volatility. Its growth strategy depends on successfully integrating acquisitions, expanding into new markets, and managing its capital needs, all of which carry execution risk.
Cosmos Health Inc. (COSM) is a vertically integrated, Greece-headquartered healthcare group that spans pharmaceutical manufacturing, wholesale distribution, branded nutraceuticals, biocides, telehealth, and early-stage drug-repurposing research. Its appeal lies in its diversified platform, international footprint, and push into higher-margin proprietary products and U.S. markets. At the same time, its recurring losses, going-concern disclosure, and micro-cap profile make it a high-risk company whose long-term viability depends on sustained revenue growth, margin improvement, and continued access to capital.
In my own analysis of stocks like COSM, I regularly use Tickeron's AI Screener to quickly compare companies across sectors using technical indicators, fundamentals, and AI signals. It helps me surface relevant ideas without sifting through thousands of tickers manually, which keeps the research process efficient and focused on my specific strategy.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
COSM saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 88 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for COSM turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 39 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
COSM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for COSM crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for COSM entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where COSM's RSI Oscillator exited the oversold zone, 38 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for COSM moved above the 200-day moving average on November 05, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +18.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where COSM advanced for three days, in 192 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
COSM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.484) is normal, around the industry mean (14.423). P/E Ratio (-0.455) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (0.850) is also within normal values, averaging (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (0.160) is also within normal values, averaging (4.260).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. COSM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COSM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalDistributors